252940-35-5

Basic information

• Product Name: 2-N-BOC-6-N-CBZ-D-LYSINOL
• Synonyms: 2-N-BOC-6-N-CBZ-D-LYSINOL ;(R)-(5-tert-Butoxycarbonylamino-6-hydroxy-hexyl)-carbamic acid benzyl ester;tert-butyl N-[(2R)-6-{[(benzyloxy)carbonyl]aMino}-1-hydroxyhexan-2-yl]carbaMate;(R)-Benzyl tert-butyl (6-hydroxyhexane-1,5-diyl)dicarbaMate;Na-Boc-Ne-Z-D-lysinol≥ 98% (HPLC)
• CAS NO: 252940-35-5
• Molecular Formula: C19H30N2O5
• Molecular Weight: 366.45
• Mol File: 252940-35-5.mol

Chemical Properties

• Boiling Point: 551.4°C at 760 mmHg
• Flash Point: 287.3°C
• Appearance: /
• Density: 1.122g/cm³
• Vapor Pressure: 5.42E-13mmHg at 25°C
• Refractive Index: 1.518
• Storage Temp.: 2-8°C
• PKA: 12.06±0.46(Predicted)
• CAS DataBase Reference: 2-N-BOC-6-N-CBZ-D-LYSINOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-N-BOC-6-N-CBZ-D-LYSINOL(252940-35-5)
• EPA Substance Registry System: 2-N-BOC-6-N-CBZ-D-LYSINOL(252940-35-5)

Safety Data

• Hazardous Substances Data: 252940-35-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-N-BOC-6-N-CBZ-D-LYSINOL is used as a key intermediate for the synthesis of peptide-based drugs and pharmaceutical compounds. Its unique structure and reactivity contribute to the development of new therapeutic agents with potential applications in various medical fields.
Used in Organic Chemistry Research:
2-N-BOC-6-N-CBZ-D-LYSINOL is utilized as a valuable building block in organic chemistry, enabling the exploration of new synthetic pathways and the creation of novel chemical entities with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C19H30N2O5/c1-19(2,3)26-18(24)21-16(13-22)11-7-8-12-20-17(23)25-14-15-9-5-4-6-10-15/h4-6,9-10,16,22H,7-8,11-14H2,1-3H3,(H,20,23)(H,21,24)/t16-/m1/s1

Upstream product

• 73548-77-3 Boc-L-Lys(Z)-OMe 
• 84890-96-0 C₂₄H₃₆N₂O₈ 
• 2389-45-9 6-(((benzyloxy)carbonyl)amino)-2-((tert butoxycarbonyl)amino)-hexanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 27894-50-4 methyl (2S)-2-amino-6-{[(benzyloxy)carbonyl]amino}hexanoate hydrochloride 
• 2389-45-9 Boc-Lys(Z)-OH 

Downstream Products

• 310870-55-4 ((S)-5,6-diaminohexyl)carbamic acid benzyl ester 

Relevant articles and documents

Synthesis and Characterization of Optically Pure Gamma-PNA Backbones by SIBX-Mediated Reductive Amination

Chiral peptide nucleic acid (PNA) is a derivative of regular PNA by introducing a chiral center to its backbone, and is known to bind more strongly to DNA or RNA than regular PNA. In particular, in the case of a γ-backbone, the L isomer stabilizes the PNA/DNA duplex, and the D-isomer has the opposite effect. Therefore, the synthesis of an optically pure γ-backbone is very important. Here, we report a novel synthetic strategy for the suppression of epimerization during the synthesis of the γ-PNA backbone. A stabilized form of 2-iodoxybenzoic acid (SIBX) was used as an oxidative reagent in the key intermediate of the N-Boc-amino acetaldehyde synthesis. This paper reports (1) the synthesis and comparison of three different γ-PNA backbones (lysine, alanine, and glutamate) by three different synthetic routes (SIBX, lithium aluminum hydride, and Red-Al) and (2) the determination of chiral purity from their derivative compounds. The enantiomeric excess purity of SIBX-mediated γ-PNA backbones was determined to be more than 99.4%, as ascertained by the high-performance liquid chromatography (HPLC) chromatogram on a standard RP-C18 column. It is comparatively higher than that of the other methods examined in this work.

Synthesis of protected 3-aminopiperidine and 3-aminoazepane derivatives using enzyme cascades

Multi-enzyme cascades utilising variants of galactose oxidase and imine reductase led to the successful conversion of N-Cbz-protected l-ornithinol and l-lysinol to l-3-N-Cbz-aminopiperidine and l-3-N-Cbz-aminoazepane respectively, in up to 54% isolated yi

Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in?vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD.

Synthesis and DNA-damaging properties of cisplatin-N-mustard conjugates

We report the synthesis of two novel cisplatin-N-mustard conjugates. In these compounds two potentially DNA-damaging molecules are combined and are separated by a spacer containing either one or four ethylene glycol units. We have shown that these conjuga

Synthesis of a series of ω-dimethylaminoalkyl substituted ethylenediamine ligands for use in enantioselective catalysis

The title compounds H2NCH((CH2)nNMe2)CH2NH2 L1-L4 (n = 1-4) are efficiently synthesized in enantiopure form. The commercial starting materials, l-asparagine, (S)-5-hydroxymethyl-2-pyrrolidinone, and (S)-6-(((benzyloxy)carbonyl)-amino)-2-((tert-butoxycarbonyl)amino)hexanoic acid, are elaborated in 6-9 standard steps to give L1 (18% overall), L2 (13%), L3 (36%) and L4 (38%) or the corresponding tris(hydrochloric acid) salts [H3NCH((CH2)nNHMe2)CH2NH3]3+ 3Cl-, which are preferable for long term storage. The sequences make use of isobutyl carbamate, Cbz, and Boc protecting groups and Hofmann type rearrangements; the dimethylamino groups are introduced at late stages, either via reductive dimethylations or nucleophilic displacements involving mesylates and HNMe2. L1-L4 chelate to [Co(en)2]3+ fragments to give octahedral complexes that catalyze numerous enantioselective reactions.

A multifaceted secondary structure mimic based on piperidine-piperidinones

Minimalist secondary structure mimics are typically made to resemble one interface in a protein-protein interaction (PPI), and thus perturb it. We recently proposed suitable chemotypes can be matched with interface regions directly, without regard for secondary structures. Here we describe a modular synthesis of a new chemotype 1, simulation of its solution-state conformational ensemble, and correlation of that with ideal secondary structures and real interface regions in PPIs. Scaffold 1 presents amino acid side-chains that are quite separated from each other, in orientations that closely resemble ideal sheet or helical structures, similar non-ideal structures at PPI interfaces, and regions of other PPI interfaces where the mimic conformation does not resemble any secondary structure. 68 different PPIs where conformations of 1 matched well were identified. A new method is also presented to determine the relevance of a minimalist mimic crystal structure to its solution conformations. Thus dld-1-faf crystallized in a conformation that is estimated to be 0.91 kcal-mol-1 above the minimum energy solution state. Do we know, when designing a new peptidomimetic scaffold like the one shown, how it can resemble secondary structures? Design and modular synthesis of this elongated mimic is reported, and the structure is related to ideal and real structures at PPI interfaces.

An expedient route for the reduction of carboxylic acids to alcohols employing 1-propanephosphonic acid cyclic anhydride as acid activator

A simple and efficient method for the synthesis of alcohols from the corresponding carboxylic acids is described. Activation of carboxylic acid with 1-propane phosphonic acid cyclic anhydride (T3P) and subsequent reduction of the intermediate phosphonic anhydride with NaBH4 yield the alcohol in excellent yields with good purity in less duration. Reduction of several alkyl/aryl carboxylic acids and Nα-protected amino acids/peptide acids as well as Nβ-protected amino acids was successfully carried out to obtain corresponding alcohols in good yields and the products characterized. The procedure is mild, safe, simple and the isolation of the products is easy.

AGONISTS THAT ENHANCE BINDING OF INTEGRIN-EXPRESSING CELLS TO INTEGRIN RECEPTORS

A method of enhancing binding of cells to an integrin-binding ligand comprises treating integrin-expressing cells in vitro with an agonist of integrin, wherein the integrin is selected from the group consisting of α4β1, α5β1, α4β7, αvβ3 and αLβ2, and contacting the treated cells with an integrin-binding ligand; integrin agonist compounds having the general formula I; methods of treating integrin-expressing cells with such agonists to enhance binding; and therapeutic methods comprising administering agonist-treated cells or agonist compounds to a mammal.

Simple and efficient synthesis of Fmoc/Boc/Cbz-protected-β-amino alcohols and peptidyl alcohols employing Boc2O

An efficient method for the activation of Fmoc/Boc/Cbz-protected amino acids using Boc2O and the reduction of the in situ generated carbonic-carbonic anhydride to their corresponding 1β-amino alcohols using sodium borohydride has been described. The method is simple, rapid and free from racemization. Besides, the protocol is also extended for the conversion of N-urethane protected peptide acids to their corresponding alcohols. Copyright

Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase

The present invention relates to the use of 2-aminothiazoline derivatives of formula: in which either R1 is a hydrogen atom or an alkyl radical and R2 is an alkyl, -alk-NH2, —CH2—R3, —CH2—S